Khan, M. S., Anker, S. D., Filippatos, G., Ferreira, J. P., Pocock, S. J., Januzzi, J. L., . . . Butler, J. (2023). Vascular disease burden, outcomes and benefits with empagliflozin in heart failure: Insights from the EMPEROR-reduced trial. Journal of cardiac failure, 29(10), . https://doi.org/10.1016/j.cardfail.2023.06.024
Chicago-Zitierstil (17. Ausg.)Khan, Muhammad Shahzeb, et al. "Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights from the EMPEROR-reduced Trial." Journal of Cardiac Failure 29, no. 10 (2023). https://doi.org/10.1016/j.cardfail.2023.06.024.
MLA-Zitierstil (9. Ausg.)Khan, Muhammad Shahzeb, et al. "Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights from the EMPEROR-reduced Trial." Journal of Cardiac Failure, vol. 29, no. 10, 2023, https://doi.org/10.1016/j.cardfail.2023.06.024.